viewOpen Orphan PLC

Open Orphan: Sustaining commercial traction

Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH).

Ulker talks through the prospects for the specialist pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals using human challenge studies.

Ulker believes Open Orphan continues to make excellent progress towards maximising the capacity utilisation of its unique clinical facilities and services capabilities.

She believes the investment case centres on continuing to leverage its differentiated portfolio of assets and services, including converting a sales pipeline of non-COVID-19 related services worth over £110m.

Click here to read Proactive Analyst Emma Ulker's latest update

Quick facts: Open Orphan PLC

Price: 29.5 GBX

Market: AIM
Market Cap: £197.47 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Open Orphan to become '$1bln firm in very near future' after COVID-19 study...

Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London's Katie Pilbeam about the world’s first COVID-19 characterisation study receiving approval from a specially convened Research Ethics Committee (REC).  This follows a contract received by the company’s subsidiary hVIVO...

1 week, 5 days ago

2 min read